Qyuns Therapeutics returns to profit at RMB 198.57 million in 1H FY26; revenue more than doubled to RMB 424.06 million

• Qyuns Therapeutics posted IFRS profit of RMB 198.57 million, swinging from a loss a year earlier; basic and diluted EPS was RMB 0.91.
• Revenue more than doubled to RMB 424.06 million, driven mainly by RMB 378.64 million from grant of licenses.
• Research and development expenses fell 35.12% to RMB 98.23 million, on lower third-party contracting costs following QX002N Phase III completion.
• Non-IFRS adjusted profit, excluding share-based payment expenses, rose to RMB 202.46 million versus an adjusted loss a year earlier.
• Pipeline updates: Crusekitug NDA for ankylosing spondylitis accepted in March 2026; Oturkibart PN and AD NDAs expected in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260819-12290974), on August 19, 2026, and is solely responsible for the information contained therein.